Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gap junction function and cancer

J W Holder1, E Elmore, J C Barrett

  • 1Genetic Toxicology Assessment Branch, EPA, Washington, DC 20460.

Cancer Research
|August 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC.

NPJ precision oncology·2025
Same author

Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer.

Oncoimmunology·2019
Same author

Rare-Variant Studies to Complement Genome-Wide Association Studies.

Annual review of genomics and human genetics·2018
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
See all related articles

Gap junctions (GJs) are crucial for cell communication, but chemicals can disrupt them, impairing tissue function and potentially leading to cancer. These disruptions affect metabolite sharing and organ integration, with significant implications for tumor progression.

Area of Science:

  • Cell Biology
  • Toxicology
  • Oncology

Background:

  • Gap junctions (GJs) facilitate essential cell-to-cell communication of metabolites and ions, enabling tissue homeostasis and waste removal.
  • Chemicals can disrupt GJ assembly, reversibly altering intercellular communication and impairing homeostatic sharing of vital substances.
  • Perturbations in GJ communication are linked to chronic effects, including cancer, as tumor promoters often inhibit GJ function.

Purpose of the Study:

  • To explore the role of gap junctions in tissue integration and homeostasis.
  • To investigate the impact of chemical-induced gap junction alterations on cellular communication.
  • To examine the involvement of gap junctions in cancer development, progression, and metastasis.

Main Methods:

  • Review of existing literature on gap junction function and chemical toxicity.

Related Experiment Videos

  • Analysis of the consequences of altered gap junction intercellular communication (GJIC) on metabolic circuits and organ integration.
  • Examination of gap junction alterations in liver precancerous foci and during tumor progression and metastasis.

    • Main Results:

    • Chemicals can reversibly alter GJ assembly and intercellular communication, disrupting homeostatic sharing of metabolites and ions.
    • Persistent GJ perturbation is associated with chronic effects, such as cancer, with tumor promoters inhibiting GJIC.
    • Gap junctions are quantitatively reduced in tumor progression and may be qualitatively altered in metastasis, affecting cell interactions at secondary sites.

    Conclusions:

    • Gap junction dysfunction disrupts tissue integration and homeostasis, contributing to disease development.
    • Alterations in gap junction communication are implicated in the progression of cancer, from precancerous foci to metastatic disease.
    • Understanding gap junction roles in cell communication and cancer is critical for developing therapeutic strategies.